BridgeBio Pharma Inc (BBIO): Utang-utang marang kapitalisasi buku

Collaboration with research centers and pharmaceutical giants expands the gene therapy capabilities of BridgeBio Pharma, Inc. (BBIO). On GURU.Markets, the ratio of debt to book capitalization demonstrates the current trend, where 0.00 serves as the actual parameter value. Growth is driven by a strategy of rapid AI-molecule implementation, while business resilience is based on inelastic demand in the rare disease segment, regardless of economic cycles.

BBIO - Utang-utang marang aset resik BridgeBio Corp ing rentang 04.07.2022 - 27.10.2026

Rincian metrik lan analitis perusahaan BridgeBio Pharma (BBIO)

- rega lan prakiraan konsensus rega:

Rega saham BridgeBio Pharma, Inc.|BBIO - Rata-rata rega prakiraan

- data kapitalisasi pasar:

Kapitalisasi pasar BridgeBio Corp|BBIO - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data kapitalisasi buku:

Nilai Buku saben Saham BridgeBio|BBIO - Pambiji Buku Bisnis|Rasio Kapitalisasi Pasar marang Nilai Buku bridgebio.com|BBIO - Total Aset Perusahaan

- data utang lan likuiditas:

Utang marang Ekuitas BridgeBio Pharma, Inc.|BBIO - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal BridgeBio Pharma Inc|BBIO - Gunggung kewajiban utang perusahaan|Utang marang nilai buku BridgeBio Corp

Analisis kabeh metrik perusahaan:BridgeBio Pharma, Inc.

This ratio measures the proportion of borrowed funds within the equity structure, allowing investors to assess the level of financial leverage and the risk of potential default. By analyzing the correlation between debt size and book value of equity, one can see how the high investment burden of BridgeBio Pharma (BBIO) on clinical developments is offset by the influx of liquidity from launching new drugs into the commercial market.

Pesaing BridgeBio Pharma, Inc.